Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000393235 | SCV000340788 | uncertain significance | not provided | 2016-03-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002494864 | SCV002784335 | uncertain significance | Adult hypophosphatasia; Childhood hypophosphatasia; Infantile hypophosphatasia | 2022-05-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000393235 | SCV003448785 | pathogenic | not provided | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 225 of the ALPL protein (p.Tyr225His). This variant is present in population databases (rs759125473, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of hypophosphatasia (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 287114). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Undiagnosed Diseases Network, |
RCV002509350 | SCV002818569 | uncertain significance | Adult hypophosphatasia | 2022-06-24 | no assertion criteria provided | clinical testing |